Marimed Inc
OTC:MRMD

Watchlist Manager
Marimed Inc Logo
Marimed Inc
OTC:MRMD
Watchlist
Price: 0.0949 USD 6.63%
Market Cap: $37.5m

Relative Value

The Relative Value of one MRMD stock under the Base Case scenario is hidden USD. Compared to the current market price of 0.0949 USD, Marimed Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRMD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MRMD Competitors Multiples
Marimed Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Marimed Inc
OTC:MRMD
37.4m USD 0.2 -2.1 8.2 101.2
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.9 37.5 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
525.7B USD 5.6 19.6 13.7 16.8
CH
Roche Holding AG
SIX:ROG
276.7B CHF 4.5 29.3 12.5 14.5
UK
AstraZeneca PLC
LSE:AZN
211.5B GBP 4.9 30.4 19.8 29
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.7 17.3 12 14
CH
Novartis AG
SIX:NOVN
221.8B CHF 5 19.5 15.6 20.1
US
Merck & Co Inc
NYSE:MRK
271.6B USD 4.2 14.3 10.1 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
146B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
US
Marimed Inc
OTC:MRMD
Average P/E: 25.2
Negative Multiple: -2.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.9
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
37%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
17.3
3%
5.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Marimed Inc
OTC:MRMD
Average EV/EBITDA: 393.5
8.2
21%
0.4
US
Eli Lilly and Co
NYSE:LLY
37.5
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.7
-1%
N/A
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.8
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
12
1%
12
CH
Novartis AG
SIX:NOVN
15.6
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Marimed Inc
OTC:MRMD
Average EV/EBIT: 1 711.4
101.2
58%
1.7
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.8
4%
4.2
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14
0%
N/A
CH
Novartis AG
SIX:NOVN
20.1
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5